FULC Stock Price, Fulcrum Therapeutics Inc Quote, Chart

Market Summary

USD7.50-0.30

Delayedas of 17 May 2024, 01:01 pm

-3.85%

FULC Stock Price

View Fullscreen

FULC RSI Chart

FULC Valuation

Market Cap

484.8M

Price/Earnings (Trailing)

-4.88

Price/Sales (Trailing)

172.83

Price/Free Cashflow

-5.24

FULC Price/Sales (Trailing)

FULC Profitability

Return on Equity

-46.55%

Return on Assets

-42.75%

Free Cashflow Yield

-19.08%

FULC Fundamentals

FULC Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

27.15%

Rev. Growth (Qtr)

14.76%

FULC Earnings

Earnings (TTM)

-99.4M

Earnings Growth (Yr)

-8.44%

Earnings Growth (Qtr)

-8.54%

Breaking Down FULC Revenue

52 Week Range

2.657.75

(Low)(High)

Last 7 days

4.1%

Last 30 days

5.4%

Last 90 days

-19.0%

Trailing 12 Months

113.4%

How does FULC drawdown profile look like?

FULC Financial Health

Current Ratio

20.38

FULC Investor Care

Shares Dilution (1Y)

0.64%

Diluted EPS (TTM)

-1.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.0M	3.0M	2.6M	2.8M
2022	17.0M	14.5M	10.7M	6.3M
2021	12.9M	15.2M	18.3M	19.2M
2020	0	0	0	8.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fulcrum Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	tourangeau greg	sold	-1,831	7.76	-236	principal accounting officer
Mar 08, 2024	tourangeau greg	sold	-57,218	11.7155	-4,884	vice president, finance
Mar 04, 2024	sapir alex	bought	492,028	11.3475	43,360	see remarks
May 10, 2023	tourangeau greg	sold	-695	3.31	-210	principal accounting officer
Jan 20, 2023	ra capital management, l.p.	bought	25,000,000	13.00	1,923,080	-
Jan 13, 2023	gould robert j	sold	-101,490	15.00	-6,766	interim president & ceo
Jan 04, 2023	ra capital management, l.p.	bought	1,314,810	7.27606	180,703	-
Dec 27, 2022	ra capital management, l.p.	bought	24,509	5.9941	4,089	-
Dec 19, 2022	ra capital management, l.p.	bought	582,814	5.8997	98,787	-
Dec 16, 2022	ra capital management, l.p.	bought	7,269,830	5.4195	1,341,420	-

Which funds bought or sold FULC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Sofinnova Investments, Inc.	sold off	-100	-193,050	-	-%
May 15, 2024	DEUTSCHE BANK AG\	unchanged	-	2,214,130	7,770,040	-%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	new	-	3,761,240	3,761,240	1.04%
May 15, 2024	Centiva Capital, LP	new	-	406,675	406,675	0.01%
May 15, 2024	Man Group plc	added	8.04	326,348	965,013	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-93.26	-2,644,240	275,353	-%
May 15, 2024	MPM BIOIMPACT LLC	new	-	10,734,300	10,734,300	1.73%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	845,324	845,324	0.22%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	new	-	9,799	9,799	-%
May 15, 2024	Rock Springs Capital Management LP	unchanged	-	1,957,440	6,869,230	0.17%

Are Funds Buying or Selling FULC?

Are funds buying FULC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FULC

No. of Funds

Unveiling Fulcrum Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	third rock ventures iii, l.p.	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	8.8%	5,469,956	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	18.8%	11,609,704	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	8.9%	5,518,881	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	2.44%	1,506,422	SC 13G/A
Jul 07, 2023	blackrock inc.	2.5%	1,514,425	SC 13G/A
Mar 06, 2023	adage capital partners gp, l.l.c.	5.63%	3,470,547	SC 13G
Feb 14, 2023	third rock ventures iii, l.p.	3.8%	1,962,202	SC 13G/A
Feb 14, 2023	rtw investments, lp	9.6%	4,993,279	SC 13G/A

Recent SEC filings of Fulcrum Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 09, 2024	4	Insider Trading
Apr 25, 2024	EFFECT	EFFECT
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Mar 20, 2024	3	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to Fulcrum Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Fulcrum Therapeutics Inc News

Latest updates

Fulcrum Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-100.0%	-	871	759	880	295	685	1,183	1,882	2,592	5,058	4,935	4,381	4,789	4,225	1,848	2,000	750
Operating Expenses	3.4%	29,834	28,863	28,199	28,172	28,235	28,658	25,538	36,117	28,590	28,617	25,705	24,063	21,832	22,012	20,952	17,924	19,546
S&GA Expenses	-100.0%	-	9,864	9,961	10,323	11,520	10,130	9,707	11,098	10,759	9,705	8,628	6,685	5,498	5,867	5,312	5,149	5,064
R&D Expenses	4.1%	19,773	18,999	18,238	17,849	16,715	18,566	15,366	25,019	17,831	18,912	17,077	17,378	16,334	16,145	15,640	12,775	14,482
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	2.00	-	1.00
Net Income	-8.5%	-26,870	-24,756	-24,017	-23,783	-24,779	-26,135	-23,738	-34,070	-25,928	-23,484	-20,716	-19,648	-16,999	-17,720	-18,962	-15,685	-18,452
Net Income Margin	-2.1%	-35.45*	-34.70*	-37.69*	-32.35*	-26.88*	-17.32*	-10.01*	-7.20*	-5.29*	-4.22*	-4.10*	-4.81*	-	-	-	-	-
Free Cashflow	-8.9%	-25,312	-23,235	-22,971	-20,980	-24,287	-19,812	-28,165	-28,684	-22,352	-22,377	-22,940	-18,386	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-9.7%	233	258	279	300	321	227	248	195	220	235	256	138	156	130	142	145	95.00	110	116	65.00	86.00
Current Assets	-10.0%	218	242	262	283	303	208	228	174	200	226	246	129	147	120	132	135	84.00	100	105	51.00	74.00
Cash Equivalents	56.3%	40.00	26.00	30.00	34.00	35.00	35.00	91.00	40.00	33.00	35.00	65.00	57.00	101	57.00	85.00	76.00	25.00	97.00	102	50.00	73.00
Net PPE	-8.6%	5.00	5.00	6.00	6.00	7.00	7.00	7.00	8.00	8.00	7.00	8.00	8.00	8.00	8.00	8.00	9.00	9.00	9.00	10.00	10.00	11.00
Liabilities	-15.6%	19.00	23.00	23.00	25.00	25.00	28.00	26.00	34.00	31.00	23.00	25.00	27.00	29.00	34.00	37.00	23.00	24.00	23.00	14.00	12.00	10.00
Current Liabilities	-21.8%	11.00	14.00	14.00	15.00	14.00	17.00	15.00	22.00	18.00	19.00	21.00	23.00	23.00	27.00	26.00	14.00	14.00	12.00	9.00	6.00	4.00
Shareholder's Equity	-9.2%	214	235	255	275	296	199	221	161	189	212	231	111	128	95.00	105	122	71.00	87.00	102	-	-
Retained Earnings	-5.3%	-536	-509	-484	-460	-437	-412	-386	-362	-328	-302	-279	-258	-238	-221	-203	-184	-169	-150	-134	-118	-68.12
Additional Paid-In Capital	0.7%	751	745	741	737	734	612	608	524	519	514	510	369	366	317	309	307	240	238	237	6.00	4.00
Shares Outstanding	0.4%	62.00	62.00	52.00	52.00	62.00	52.00	52.00	41.00	41.00	41.00	41.00	33.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	163,560	-	-	-	136,819	-	-	-	249	-	-	-	240	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-9.2%	-25,284	-23,158	-22,906	-20,785	-24,116	-19,696	-27,882	-27,366	-22,106	-21,858	-22,573	-17,821	-16,226	-19,826	-4,504	-14,121	-15,204	-4,495	-13,017	-12,074	-9,897
Share Based Compensation	13.5%	3,916	3,449	3,737	3,363	4,253	3,271	3,353	2,879	3,847	3,793	2,658	2,546	2,073	1,677	1,776	2,204	1,693	1,274	1,179	950	821
Cashflow From Investing	107.7%	38,128	18,354	19,020	19,875	-93,941	-36,362	-2,279	31,395	19,659	-9,094	-106,636	-26,354	12,415	-14,598	14,090	-226	-56,404	-108	-214	-221	-401
Cashflow From Financing	475.3%	1,651	287	-	142	117,693	218	80,946	2,811	348	891	137,903	209	47,504	6,255	-83.00	64,686	274	-281	65,200	-529	-47.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FULC Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 0	$ 295
Operating expenses:
Research and development	19,773	16,715
General and administrative	10,061	11,520
Total operating expenses	29,834	28,235
Loss from operations	(29,834)	(27,940)
Other income, net	2,964	3,161
Net loss	$ (26,870)	$ (24,779)
Net loss per share, basic	$ (0.43)	$ (0.41)
Net loss per share, diluted	$ (0.43)	$ (0.41)
Weighted-average common shares outstanding, basic	61,984	59,722
Weighted-average common shares outstanding, diluted	61,984	59,722
Comprehensive loss:
Net Income (Loss)	$ (26,870)	$ (24,779)
Other comprehensive gain (loss):
Unrealized (loss) gain on marketable securities	(298)	146
Total other comprehensive (loss) gain	(298)	146
Comprehensive loss	$ (27,168)	$ (24,633)

FULC Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 39,949	$ 25,563
Marketable securities	173,365	210,658
Unbilled accounts receivable	0	537
Prepaid expenses and other current assets	4,638	5,441
Total current assets	217,952	242,199
Property and equipment, net	4,765	5,216
Operating lease right-of-use assets	6,682	7,176
Restricted cash	1,201	1,092
Other assets	1,988	2,011
Total assets	232,588	257,694
Current liabilities:
Accounts payable	3,857	2,757
Accrued expenses and other current liabilities	4,805	8,726
Operating Lease Liability, current	2,032	2,192
Total current liabilities	10,694	13,675
Operating lease liability, excluding current portion	8,105	8,629
Other liabilities, excluding current portion	197	197
Total liabilities	18,996	22,501
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized; 62,141,011 and 61,915,367 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	62	62
Additional paid-in capital	750,507	744,940
Accumulated other comprehensive loss	(434)	(136)
Accumulated deficit	(536,543)	(509,673)
Total stockholders’ equity	213,592	235,193
Total liabilities and stockholders’ equity	$ 232,588	$ 257,694

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Alexander C. Sapir
WEBSITE	fulcrumtx.com
INDUSTRY	Biotechnology
EMPLOYEES	89

Fulcrum Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Fulcrum Therapeutics Inc? What does FULC stand for in stocks?

FULC is the stock ticker symbol of Fulcrum Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulcrum Therapeutics Inc (FULC)?

As of Thu May 16 2024, market cap of Fulcrum Therapeutics Inc is 484.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FULC stock?

You can check FULC's fair value in chart for subscribers.

What is the fair value of FULC stock?

You can check FULC's fair value in chart for subscribers. The fair value of Fulcrum Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fulcrum Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FULC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fulcrum Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FULC is over valued or under valued. Whether Fulcrum Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fulcrum Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FULC.

What is Fulcrum Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, FULC's PE ratio (Price to Earnings) is -4.88 and Price to Sales (PS) ratio is 172.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FULC PE ratio will change depending on the future growth rate expectations of investors.